Philip M Arlen Selected Research

Fowlpox

9/2015	A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
7/2009	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
8/2008	Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
5/2008	Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
10/2007	Clinical safety of a viral vector based prostate cancer vaccine strategy.
4/2007	PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
6/2006	A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).
5/2005	Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
2/2005	Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
2/2005	Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip M Arlen Research Topics

Disease

54	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 10/2002
43	Neoplasms (Cancer) 06/2022 - 01/2003
13	Vaccinia 09/2015 - 10/2002
11	Carcinoma (Carcinomatosis) 06/2022 - 02/2005
10	Fowlpox 09/2015 - 02/2005
8	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2004
7	Disease Progression 09/2007 - 05/2004
6	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 01/2011
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2012
3	Fatigue 01/2021 - 10/2005
3	Breast Neoplasms (Breast Cancer) 08/2016 - 06/2006
2	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 11/2011
2	Injection Site Reaction 11/2015 - 03/2014
2	Colonic Neoplasms (Colon Cancer) 06/2013 - 01/2012
1	Mastodynia 01/2021
1	Anemia 01/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Constipation 01/2020
1	Diarrhea 01/2020
1	Nausea 01/2020
1	Vomiting 01/2020
1	Circulating Neoplastic Cells 01/2017
1	Chordoma 11/2015
1	Edema (Dropsy) 11/2015
1	Adenocarcinoma 06/2013
1	Exanthema (Rash) 05/2012
1	Colitis 05/2012
1	Neutropenia 05/2012
1	Hematologic Neoplasms (Hematological Malignancy) 06/2009
1	Osteonecrosis (Kienbock's Disease) 02/2009
1	Secondary Hyperparathyroidism 09/2007

Drug/Important Bio-Agent (IBA)

44	VaccinesIBA 08/2016 - 10/2002
21	AntigensIBA 01/2020 - 08/2003
19	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 10/2002
18	AndrogensIBA 01/2021 - 10/2002
12	Monoclonal AntibodiesIBA 06/2022 - 12/2005
12	Docetaxel (Taxotere)FDA Link 01/2021 - 01/2003
11	Cancer VaccinesIBA 11/2015 - 05/2005
9	Carcinoembryonic AntigenIBA 06/2022 - 08/2003
6	Immunoglobulin G (IgG)IBA 06/2022 - 01/2012
6	Peptides (Polypeptides)IBA 08/2016 - 08/2003
6	Thalidomide (Thalomid)FDA Link 04/2010 - 01/2003
6	Hormones (Hormone)IBA 03/2009 - 08/2005
6	VA 061 (VA061)IBA 01/2008 - 01/2003
5	PROSTVACIBA 01/2021 - 07/2009
5	EpitopesIBA 01/2011 - 08/2003
4	Prednisone (Sone)FDA LinkGeneric 01/2021 - 02/2009
4	ensituximabIBA 01/2020 - 01/2011
4	Neoplasm Antigens (Tumor Antigens)IBA 06/2013 - 02/2005
3	Testosterone (Sustanon)FDA Link 01/2021 - 05/2004
3	Biomarkers (Surrogate Marker)IBA 01/2017 - 05/2004
3	Bevacizumab (Avastin)FDA Link 10/2016 - 02/2009
3	Lenalidomide (CC 5013)FDA Link 10/2016 - 03/2004
3	Proteins (Proteins, Gene)FDA Link 08/2016 - 12/2005
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2015 - 02/2005
3	sipuleucel-T (APC8015)FDA Link 08/2013 - 03/2011
3	Ketoconazole (Nizoral)FDA LinkGeneric 06/2010 - 12/2002
3	Diphosphonates (Bisphosphonates)IBA 02/2009 - 12/2002
2	Complement System Proteins (Complement)IBA 06/2022 - 01/2017
2	enzalutamideIBA 01/2021 - 08/2013
2	Biological ProductsIBA 01/2020 - 09/2016
2	abirateroneIBA 08/2013 - 01/2006
2	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2010 - 08/2007
2	Sorafenib (BAY 43-9006)FDA Link 06/2009 - 01/2008
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 02/2009 - 12/2005
2	nilutamide (Nilandron)FDA Link 07/2008 - 03/2005
2	DNA (Deoxyribonucleic Acid)IBA 10/2007 - 12/2005
2	Antineoplastic Agents (Antineoplastics)IBA 03/2007 - 01/2006
2	Androgen Antagonists (Antiandrogens)IBA 08/2005 - 03/2005
1	Cell Adhesion MoleculesIBA 06/2022
1	cabozantinibIBA 01/2021
1	BilirubinIBA 01/2020
1	LigandsIBA 04/2019
1	ALT-803IBA 04/2019
1	Interleukin-15 (Interleukin 15)IBA 04/2019
1	carotuximabIBA 01/2017
1	Tissue ExtractsIBA 01/2017
1	OsteopontinIBA 01/2017
1	EndoglinIBA 01/2017
1	TARPIBA 08/2016
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 08/2016
1	Transcription Factors (Transcription Factor)IBA 11/2015
1	Brachyury protein (Brachyury)IBA 11/2015
1	yeast-CEA vaccineIBA 03/2014
1	Immunoglobulins (Immunoglobulin)IBA 06/2013
1	Androgen Receptors (Androgen Receptor)IBA 03/2013
1	Transaminases (Aminotransferases)IBA 05/2012
1	IpilimumabIBA 05/2012
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2012
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 03/2009
1	CytokinesIBA 02/2009
1	CD58 Antigens (LFA-3)IBA 05/2008
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 05/2008

Therapy/Procedure

25	Therapeutics 01/2021 - 08/2003
16	Immunotherapy 06/2022 - 12/2005
12	Castration 01/2021 - 07/2008
9	Drug Therapy (Chemotherapy) 01/2020 - 02/2006
5	Radiotherapy 11/2011 - 05/2005
1	Cytoreduction Surgical Procedures 01/2020
1	Investigational Therapies (Experimental Therapy) 03/2012